VEGFA and hepatocellular carcinoma: A global, open-label, phase 3 IMbrave150 trial established that treatment with atezolizumab plus anti-VEGF antibody (bevacizumab) resulted in better OS and PFS outcomes than sorafenib in patients with advanced HCC (141).